Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Titel:
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Auteur:
Wykoff, Charles C Abreu, Francis Adamis, Anthony P Basu, Karen Eichenbaum, David A Haskova, Zdenka Lin, Hugh Loewenstein, Anat Mohan, Shaun Pearce, Ian A Sakamoto, Taiji Schlottmann, Patricio G Silverman, David Sun, Jennifer K Wells, John A Willis, Jeffrey R Tadayoni, Ramin